FDA Concerned About Yaz

The FDA is remaining concerned about a type of birth control pill that could raise the risk of blood clots more than other pills on the market. The pills known as Yaz or Yasmin, marketed by Bayer AG, contain drospirenone. Drospirenone is a type of female sex hormone called a progestin.

Although all birth control pills raise the risk of blood clots, some studies have reported that the risk of blood clots for women who use birth-control pills containing drospirenone is higher than that for women who use birth-control pills containing levonorgestrel. Blood clots form inside a vein and are known as deep vein thrombosis, or DVT. The clots usually form in the lower leg or thigh, but can break loose and travel to other areas of the body such as the lungs, where they are called a pulmonary embolism, or PE.

Bayer maintains that scientific evidence shows that the risk is comparable to that of other birth control pills. Be on the lookout for symptoms of DVT, including persistent leg pain, persistent chest pain, and sudden shortness of breath.

Related posts:

1. FDA Reviews Birth Control Blood Clot Risk The Food and Drug Administration is reviewing the risk of...
2. Birth Control Pills Containing Drospirenone: Possible Increased Risk of Blood Clots Audience: OBGYN, Family Practice, Patient ISSUE: FDA is aware of...
3. Bristol Meyers-Squibb Recalls Lot of Blood-Thinner Coumadin Bristol-Myers Squibb is voluntarily recalling one lot—or over 1.8 million...
4. HeartWare Device Has 9.2 Thrombosis Rate In Study New data presented at the International Society of Heart and...
5. Higher Bleeding Rates Detected in J&J-Bayer Drug A heart drug from Johnson & Johnson and Bayer AG...